http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2886635-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbe8dc04241d4ed47d74dcaae607b097 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09de3efe5c479530a6a3f235304cf5a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcb6a331935095f8a8de57ed28c67970 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6534575548e2f355d4935dd768aa98e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c59a07d059d672a8cc7772e1c92b5a8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6880bf0c37bf4077ae4985b31bb6586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ccbfcca4a25073c1eb317885acee8b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da8fa5793783b9adcdf22d2abae22564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb0c757fe2e56dee0f67895a8bf62b58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31211bae2a262eb4cb629a99aef28862 |
| publicationDate | 2021-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2886635-T3 |
| titleOfInvention | Immunomodulators |
| abstract | A compound of formula (I) **(See formula)** or a pharmaceutically acceptable salt thereof, in which: **(See formula)** A is in which: indicates the point of attachment to the carbonyl group and indicates the point of attachment to the nitrogen atom; z is 0; w is 1; R1 is phenylC1-C3alkyl, where phenyl is optionally substituted with hydroxyl; R2 is C1-C7alkyl; R3 -CH2C(O)NH2 R5 is selected from C1-C7alkyl and -CH2(imidazolyl) optionally substituted with CF3C(O)-; R6 is selected from C1-C7alkyl and -(CH2)2C(O)NH2, or R3 and R6 together form a bridge containing from 2 to 7 carbon atoms, optionally a double bond, and optionally a -C(O) group. NH- or -NHC(O)-; R7 is hydrogen, or R7 and R16 together form a bridge containing from 2 to 7 carbon atoms, optionally a double bond, and optionally a -C(O)NH- or -NHC(O)- group; or R7 and Rg, together with the atoms to which they are attached, form a pyrrolidine ring optionally substituted with a hydroxyl group; R8 is -(CH2)indolyl; R9 is selected from hydroxymethyl and -CH2CH2CO2H; R10 is selected from -(CH2)indolyl and -(CH2)benzothienyl, each optionally substituted with -CH2CO2H; R11 and R12 are C1-C7alkyl; and R13 is selected from C1-C7alkyl and -(CH2)3NHC(NH)NH2, or R9 and R13 together form a bridge containing from 2 to 7 carbon atoms, optionally a double bond, and optionally a -C(O )NH- or -NHC(O)- R14 and R15 are hydrogen; R16 is selected from hydrogen, -CHR17C(O)NH2, -CHR17C(O)NHCHR18C(O)NH2 and -CHR17C(O)NHCHR18C(O)NHCH2C(O)NH2 R17 is selected from hydrogen and -CH2OH; R18 is selected from hydrogen and methyl; provided that at least one of R3 and R6; R9 and R13, and R7 and R16 form a bridge; Ra is selected from hydrogen and methyl; Rb is methyl or, Rb and R2, together with the atoms to which they are attached, form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxyl; Rc is hydrogen; Rd and R4, together with the atoms to which they are attached, form a pyrrolidine ring; wherein said ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, hydroxyl and phenyl; Re is hydrogen or methyl, or Re and R5, together with the atoms to which they are attached, form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine, and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy; Rf is hydrogen; Rg is hydrogen or methyl or R ≡ and R7, together with the atoms to which they are attached, may form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, benzyl optionally substituted with a halo group, benzyloxy, cyano, cyclohexyl, methyl, halo, hydroxyl, isoquinolinyloxy optionally substituted with a methoxy group, quinolinyloxy optionally substituted with a halo group and tetrazolyl; and wherein the pyrrolidine and piperidine ring are optionally fused to a cyclohexyl, phenyl or indole group; Rh and Ri are hydrogen; Rj is selected from hydrogen and methyl; Rk is hydrogen or methyl, or Rk and R11, together with the atoms to which they are attached, form a ring selected from azetidine, pyrrolidine, morpholine, piperidine, piperazine and tetrahydrothiazole; wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo, and hydroxy; R1 is methyl or, R1 and R12, together with the atoms to which they are attached, form a ring selected from azetidine and pyrrolidine, wherein each ring is optionally substituted with one to four groups independently selected from amino, cyano, methyl, halo and hydroxyl; Rm and Rn are hydrogen; and Rz is -C(O)NHR16. |
| priorityDate | 2016-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 652.